生殖激素和蛋白質檢測市場：市場規模（按細分市場）、份額、監管、報銷、預測（~2033）

生殖激素和蛋白質測試包括抗苗勒氏管激素(AMH) 實驗室測試、雌二醇實驗室測試、黃體酮實驗室測試、硫酸脫氫表雄酮(DHEAS) 實驗室測試、催乳素實驗室測試、睪固酮實驗室測試、黃體生成素實驗室測試(LH)實驗室測試、卵泡刺激素 (FSH) 實驗室測試等。

生殖激素和蛋白質測試用於評估男性和/或女性的生育能力，包括促性腺激素低下性腺功能減退症、高催乳素血症、纖毛功能障礙、囊性纖維化，以及與某些疾病相關的疾病，例如沙眼衣原體和淋病奈瑟菌等性傳染病。

本報告深入探討了全球生殖激素和蛋白質檢測市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響以及區域和國家趨勢。

目錄

目前上市的生殖激素及蛋白質測試及競爭格局

• 對主要產業趨勢的見解
• 生殖激素和蛋白質檢測按細分市場劃分的市場總收入以及 2015-2033 年市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• 生殖激素和蛋白質檢測市場的SWOT分析
• 生殖激素和蛋白質檢測市場的競爭動態洞察和趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

Reproductive Hormones and Proteins Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Reproductive Hormones and Proteins tests market for the year 2020 and beyond. The Reproductive Hormones and Proteins tests include

Anti-Mullerian Hormone (AMH) lab Test, Estradiol lab Test, Progesterone lab Test, Dehydroepiandrosterone Sulphate (DHEAS) lab Test, Prolactin lab Test, Testosterone lab Test, Luteinizing Hormone (LH) lab Test, and Follicle-Stimulating Hormone (FSH) lab Test.

Reproductive Hormones and Proteins tests are performed to evaluate fertility in men and/or women and is associated with specific diseases such as hypogonadotropic hypogonadism, hyperprolactinemia, ciliary function disorders, cystic fibrosis, and sexually transmitted infections such as Chlamydia trachomatis and Neisseria gonorrhoeae.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Reproductive Hormones and Proteins Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Reproductive Hormones and Proteins Tests market revenue by segment and market outlooks from 2015- 2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Reproductive Hormones and Proteins Tests market.
• Competitive dynamics insights and trends provided for Reproductive Hormones and Proteins Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Danaher Corp, Abbott Laboratories, Siemens AG, Quidelortho Corp, F. Hoffmann-La Roche Ltd, Tosoh Corp, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Reproductive Hormones and Proteins Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Reproductive Hormones and Proteins Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Reproductive Hormones and Proteins Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Reproductive Hormones and Proteins Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Reproductive Hormones and Proteins Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable